- Details
- In this discussion, Sam Chang interviews Saum Ghodoussipour about the role of circulating tumor DNA (ctDNA) as a biomarker in urothelial carcinoma. Dr. Ghodoussipour presents an overview of ctDNA's potential applications in various stages of bladder cancer, from non-muscle invasive to advanced disease. He highlights its utility in early detection, risk stratification, and monitoring treatment resp...
|
- Details
- Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy. Dr. Crispen discusses the findings, which show that patients with a history of upper tract disease experience bladder tumor recurrences sooner than those with primary bladder tumors, despite similar overall recurrence rates. The study reveals a higher ris...
|
- Details
- Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase one study showing promising results with minimal toxicity. The treatment activates dendritic cells, leading to CD8+ T cell recruitment and tumor elimination. Preliminary data indicates a 50% complete...
|
- Details
- Sam Chang interviews Sunil Patel about the Orion Bladder Cancer Study. The phase 3 single-arm study evaluates the efficacy and safety of a paclitaxel-hyaluronic acid conjugate, ONCOFID-P-B, administered intravesically for patients with BCG-unresponsive CIS of the bladder. This novel agent targets CD44, overexpressed in bladder cancer cells, and has shown promising results with a high complete resp...
|
- Details
- Sam Chang interviews Roger Li about the MoonRISe-1 trial. This phase 3 study explores the use of TAR-210, an innovative intravesical delivery system for the tyrosine kinase inhibitor erdafitinib, targeting patients with intermediate-risk non-muscle-invasive bladder cancer harboring FGFR alterations. Dr. Li explains that TAR-210, administered via a quick in-office procedure, continuously releases e...
|
- Details
- Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment. Speaking with Dr. Sam Chang of Vanderbilt, Dr. Porten explains that TAR-200 releases gemcitabine directly into the bladder over a sustained period, offeri...
|
- Details
- José Daniel Subiela Henriquez presented findings from his multicenter study on BCG therapy for very high-risk non-muscle-invasive bladder cancer (NMIBC). Dr. Subiela's research evaluates the effectiveness of BCG in a group where the European Association of Urology (EAU) had recommended radical cystectomy due to high progression risks. His study, involving 640 patients over 13 years, suggests that...
|
- Details
- Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. Microhematuria, a common condition affecting millions annually in the U.S., is frequently o...
|
- Details
- Ashish Kamat hosts a discussion with Roger Li and Trinity Bivalacqua on the CORE-001 study evaluating cretostimogene grenadenorepvec and pembrolizumab for BCG-unresponsive CIS. Dr. Li highlights the 83% complete response rate at any time, 57.1% at 12 months, and 54.3% at 24 months, noting the therapy's durability and lack of progression to muscle-invasive or metastatic disease. The combination the...
|
- Details
- Sam Chang interviews Edward Messing about his research on using apalutamide for non-muscle invasive bladder cancer. Dr. Messing discusses a trial aiming to explore whether antiandrogens like apalutamide can prevent bladder cancer recurrence, given its higher prevalence in men. This molecular proof-of-principle study, sponsored by the National Cancer Institute, focuses on the role of androgen recep...
|
